PPAR Research

PPAR Research / 2019 / Article

Corrigendum | Open Access

Volume 2019 |Article ID 4309068 | 2 pages | https://doi.org/10.1155/2019/4309068

Corrigendum to “PPARs in Human Neuroepithelial Tumors: PPAR Ligands as Anticancer Therapies for the Most Common Human Neuroepithelial Tumors”

Received18 Jun 2019
Accepted20 Jun 2019
Published21 Jul 2019

The article titled “PPARs in Human Neuroepithelial Tumors: PPAR Ligands as Anticancer Therapies for the Most Common Human Neuroepithelial Tumors” [1] was found to contain material in Sections 1, 2, and 3 from published work and to have missing attributions and errors in citations. The articles are as follows:(i)M. T. Heneka and G. E. Landreth, “PPARs in the brain,” Biochimica et Biophysica Acta, vol. 1771, no. 8, pp. 1031–1045, 2007. https://doi.org/10.1016%2fj.bbalip.2007.04.016. [2] (Cited as reference [36]).(ii)Lars Tatenhorst, Eric Hahnen, and Michael T. Heneka, “Peroxisome Proliferator-Activated Receptors (PPARs) as Potential Inducers of Antineoplastic Effects in CNS Tumors,” PPAR Research, vol. 2008, Article ID 204514, 9 pages, 2008. https://doi.org/10.1155/2008/204514. [3] (not cited).(iii)Markus P. Kummer and Michael T. Heneka, “PPARs in Alzheimer’s Disease,” PPAR Research, vol. 2008, Article ID 403896, 8 pages, 2008. https://doi.org/10.1155/2008/403896. [4] (not cited).(iv)J. N. Feige, L. Gelman, L. Michalik, B. Desvergne, and W. Wahli, “From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions,” Progress in Lipid Research, vol. 45, no. 2, pp. 120–159, 2006. https://doi.org/10.1016%2fj.plipres.2005.12.002. [5] (cited as reference [30]).(v)A. Cimini, E. Benedetti, L. Cristiano et al., “Expression of peroxisome proliferator-activated receptors (PPARs) and retinoic acid receptors (RXRs) in rat cortical neurons,” Neuroscience, vol. 130, no. 2, pp. 325–337, 2005. https://doi.org/10.1016%2fj.neuroscience.2004.09.043. [6] (cited as reference [81]).

References

  1. E. Benedetti, R. Galzio, B. D'Angelo, M. P. Cer, and A. Cimini, “PPARs in human neuroepithelial tumors: PPAR ligands as anticancer therapies for the most common human neuroepithelial tumors,” PPAR Research, vol. 2010, Article ID 427401, 9 pages, 2010. View at: Publisher Site | Google Scholar
  2. M. T. Heneka and G. E. Landreth, “PPARs in the brain,” Biochimica et Biophysica Acta (BBA)—Molecular and Cell Biology of Lipids, vol. 1771, no. 8, pp. 1031–1045, 2007. View at: Publisher Site | Google Scholar
  3. L. Tatenhorst, E. Hahnen, and M. T. Heneka, “Peroxisome proliferator-activated receptors (PPARs) as potential inducers of antineoplastic effects in CNS tumors,” PPAR Research, vol. 2008, Article ID 204514, 9 pages, 2008. View at: Publisher Site | Google Scholar
  4. M. P. Kummer and M. T. Heneka, “PPARs in alzheimer's disease,” PPAR Research, vol. 2008, Article ID 403896, 8 pages, 2008. View at: Publisher Site | Google Scholar
  5. J. N. Feige, L. Gelman, L. Michalik, B. Desvergne, and W. Wahli, “From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions,” Progress in Lipid Research, vol. 45, no. 2, pp. 120–159, 2006. View at: Publisher Site | Google Scholar
  6. A. Cimini, E. Benedetti, L. Cristiano et al., “Expression of peroxisome proliferator-activated receptors (PPARs) and retinoic acid receptors (RXRs) in rat cortical neurons,” Neuroscience, vol. 130, no. 2, pp. 325–337, 2005. View at: Publisher Site | Google Scholar

Copyright © 2019 Elisabetta Benedetti et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

375 Views | 242 Downloads | 0 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.